All In Biotech

Drug Trial Radar · NCT07791199

Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers

A Continuation Protocol for Deucravacitinib in Adult Patients With Systemic Lupus Erythematosus (SLE) or Sjögren's Disease (SjD) and Pediatric Patients With Psoriasis (PsO) or Psoriatic Arthritis (PsA) Who Have Completed Parent Studies

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

2,300

Planned (sponsor's estimate)

Start

Dec 31, 2026

Primary completion

Oct 31, 2030

Study completion Oct 31, 2030

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have completed their qualified parent studies and/or long-term extension if applicable.

Conditions

  • Systemic Lupus Erythematosus
  • Sjögren's Disease
  • Psoriasis
  • Psoriatic Arthritis

Interventions

  • DeucravacitinibDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants treatedTime frame: Up to approximately 28 days after last dose of deucravacitinib

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.